Actively Recruiting

Phase Not Applicable
Age: 18Years - 45Years
All Genders
NCT05023785

The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial

Led by University Health Network, Toronto · Updated on 2025-11-26

336

Participants Needed

1

Research Sites

165 weeks

Total Duration

On this page

Sponsors

U

University Health Network, Toronto

Lead Sponsor

C

Centre hospitalier de l'Université de Montréal (CHUM)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Pediatric, adolescent and young adult cancer survivors (PAYA-CS) are at higher risk of cardiovascular (CV) morbidity and mortality. This is a consequence of prior cancer-related therapies that have the potential of producing cardiac dysfunction, reducing cardiorespiratory fitness (reduced VO2peak) and psychosocial morbidities (i.e., anxiety and depression). A reduction of physical activity levels can evoke functional limitations resulting in a vicious cycle of reduced exercise tolerance and physical deterioration. To date, there is limited evidence on the use of non-pharmacological strategies such as Cardio-Oncology Rehabilitation (CORE) including structured exercise, behavioural support and risk factor management to improve the outcomes of this underserved population. The HIMALAYAS study is a randomized controlled trial designed to evaluate the impact of a CORE intervention (consisting of six-months home and onsite-based structured moderate to high-intensity aerobic exercise training and CVD risk factor management) on CV and psychosocial health, and the cardiovascular disease risk in PAYA-CS with mild heart dysfunction (stage B heart failure) compared to standard of care (i.e. providing guidance on the current exercise recommendations for cancer survivors). The primary objective of the HIMALAYAS study is to determine whether a six-month supervised CORE intervention, consisting of individualized moderate to high-intensity aerobic exercise training, CVD risk factor modification and enhanced online behavioral support, improves cardiorespiratory fitness (VO2peak; primary outcome), cardiac function, CVD risk factors and biomarkers, and patient-reported outcomes (PROs) at six- months follow-up compared to standard of care (CON) in PAYA-CS with stage B heart failure. The secondary objective is to assess the same outcomes at 12- and 24-months follow-up. We will recruit 336 patients across 5 sites in Canada and upto 134 patients at UHN in 3 years and conclude in 6 years.

CONDITIONS

Official Title

The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial

Who Can Participate

Age: 18Years - 45Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be a pediatric, adolescent, or young adult cancer survivor diagnosed at 39 years of age or younger
  • Be between 18 and 45 years old at enrollment
  • Have received cancer treatments with known heart risks such as anthracyclines, trastuzumab, radiotherapy, platinum-based agents, VEGF inhibitors, or tyrosine kinase inhibitors
  • Be cancer-free at enrollment
  • Have stage B heart failure defined by specific heart function measures or biomarkers
Not Eligible

You will not qualify if you...

  • Have any absolute or unresolved relative contraindications to exercise
  • Have untreated physical or mental health issues that prevent safe exercise
  • Have established cardiovascular disease except mild heart dysfunction described
  • Be pregnant at the time of recruitment
  • Currently engage in frequent high-intensity exercise (more than one session per week)
  • Have significant barriers to participation such as living far from the study center or inability to comply with the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Health Network

Toronto, Ontario, Canada, M5G2C4

Actively Recruiting

Loading map...

Research Team

P

Paaladinesh Thavendiranathan, MD

CONTACT

N

Nilina Mohabir, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here